Drug development for IPF
Search documents
Trevi Therapeutics plans two pivotal phase III trials for IPF-related chronic cough as FDA alignment achieved (NASDAQ:TRVI)
Seeking Alpha· 2026-03-18 07:03
Management View - Trevi Therapeutics reported that 2025 was a significant inflection point for growth, driven by positive data readouts from the CORAL trial in patients with idiopathic pulmonary fibrosis (IPF) [2]
